Giovanni Palladini, Pavia, Italy
Carlos Fernández de Larrea, Barcelona, Spain
OP27Prevalence and survival impact of atrial fibrillation in patients with transthyretin cardiac amyloidosis. Analysis from a large international cohort
Adrián Rivas Pérez, Madrid, Spain
OP28Impact on survival of N-terminal Pro-B-type natriuretic peptide (NT-proBNP) increase after diagnosis for cardiac transthyretin amyloidosis
Silvia Oghina, Créteil, France
OP29Diagnostic value of subcutaneous abdominal fat tissue aspirates in cardiac amyloidosis
Hans Nienhuis, Groningen, The Netherlands
OP30Describing the echocardiographic phenotype of transthyretin cardiac amyloidosis - What are the predictors of prognosis?
Liza Chacko, London, UK
OP31Cardiac transthyretin wild type amyloidosis (ATTRwt): A prospective study of 400 patients followed at the Italian referral center
Paolo Milani, Pavia, Italy
OP32Regional cardiac uptake of 99-Tc-DPD is a novel powerful and independent prognostic marker in cardiac ATTR wild type amyloidosis
Paolo Milani, Pavia, Italy
OP33Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival
Sari Atula, Helsinki, Finland
OP34Excellent outcomes of isolated renal transplantation for hereditary fibrinogen (AFib) amyloidosis
Hugh Goodman, Hamilton, New Zealand
14:56 – 15:20Discussion
María Teresa Cibeira, Barcelona, Spain
Ramón Lecumberri, Pamplona, Spain
OP35A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated ALl amyloidosis (SWOG S1702; NCT#03499808)
Terri Parker, CT, USA
OP36Ixazomib-dexamethasone versus physician’s choice in relapsed/refractory systemic AL amyloidosis: Results from the phase 3 tourmaline-AL1 trial
Angela Dispenzieri, Rochester, MN, USA
OP37Subcutaneous daratumumab + cyclophosphamide/bortezomib/dexamethasone in newly diagnosed AL amyloidosis: Updated safety run-in results of ANDROMEDA
Vaishali Sanchorawala, Boston, MA, USA
OP38Assessment of minimal residual disease using multiparametric flow cytometry in treated patients with AL amyloidosis
Andrew Staron, Boston, MA, USA
OP39One-year evaluation of the incidence and distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
Ute Hegenbart, Heidelberg, Germany
OP40Localised laryngeal amyloid – A series of 100 cases
Helen Lachmann, London, UK
16:12 - 16:30Discussion
ATTR Amyloidosis: Unlocking the potential of RNAi therapeutics
Mathew Maurer, New York, USA
Mechanisms of organ damage in ATTR amyloidosis
Julian Gillmore, London, UK
Controlling gene expression with RNAi in ATTR amyloidosis
Laura Obici, Pavia, Italy
Interfering with hereditary ATTR amyloidosis using RNAi
David Adams, Paris, France
Giampaolo Merlini, Pavia, Italy
Stefan Schönland, Heidelberg, Germany
Vaishali Sanchorawala, Boston, MA, USA
Arnaud Jaccard, Limoges, France
Bouke Hazenberg, Groningen, The Netherlands
Bruno Paiva, Pamplona, Spain
Ramón Lecumberri, Pamplona, Spain
• When to suspect AL amyloidosis during MGUS follow-up?
• New response criteria needed?
• Is there a role for MRD assessment?
• Are we curing AL amyloidosis in 2020?
• Amyloid deposition in organ transplant recipients?
Hartmut Schmidt, Münster, Germany
Ole Suhr, Umeå, Sweden
Violaine Plante-Bordeneuve, Créteil, France
Esther González-López, Madrid, Spain
Joel Buxbaum, La Jolla, CA, USA
Juan González-Moreno, Palma de Mallorca, Spain
Philip Hawkins, London, UK
• What is the real prevalence of wild type ATTR amyloidosis?
• What are the critical endpoints in ATTR polyneuropathy?
• Best treatment approach at lack of response to patisiran or inotersen?
• Is it time for combination therapy trials?
• What is the best approach to ATTR mutant carriers?